Home › Stomatitis › NCT05335434

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

A Single Center Pilot Study of Intraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
* Age ≥18 years.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.
* Participants who have a history of radiation therapy to the head and neck.
* Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
* Participants who are planned to receive palifermin for OM prevention.

About the study

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device.

The name of the study device involved in this study is:

\- THOR LX2.3 with LED Lollipop

What is being tested

• THOR LX2.3 with LED Lollipop (device)

Sponsor: Dana-Farber Cancer Institute · Participants: 20 · Started: Jun 10, 2022

Contact the study team

• Kentaro Ikeda, DDS,MPH · Phone: 617-732-6570

Official record on ClinicalTrials.gov — NCT05335434

Locations in the U.S.

Conditions

• Stomatitis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.